REG - Adv Medical Solutns. - Total Voting Rights

Advanced Medical SolutionsAnnouncement

30/01/2026 16:15

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260130:nRSd1650Ra&default-theme=true

RNS Number : 1650R  Advanced Medical Solutions Grp PLC  30 January 2026

 

30 January 2026

Advanced Medical Solutions Group plc

("AMS" or the "Group")

 

Total Voting Rights

 

In accordance with Disclosure and Transparency Rule 5.6.1, the issued share
capital of Advanced Medical Solutions Group plc as at 30 January 2026
comprises 219,584,690 ordinary shares of 5p each with voting rights. There are
no shares held in treasury.

 

The above figure may be used by shareholders as the denominator for the
calculations by which they will determine if they are required to notify their
interest in, or a change to their interest in, the Company under the FCA's
Disclosure and Transparency Rules.

 

- End -

 

For further information, please visit www.admedsol.com
(http://www.admedsol.com) or contact:

 

 Advanced Medical Solutions Group plc        Tel: +44 (0) 1606 545508
 Chris Meredith, Chief Executive Officer

 Eddie Johnson, Chief Financial Officer

 Michael King, Investor Relations

 Optimum Strategic Communications            Tel: +44 (0) 20 4566 8543
 Mary Clark / Nick Bastin / Isabelle Abdou   AMS@optimumcomms.com

 Investec Bank PLC (NOMAD & Broker)          Tel: +44 (0) 20 7597 5970
 Gary Clarence / David Anderson

 Berenberg (Joint Broker)                    Tel: +44 (0)20 3207 7800
 Toby Flaux / Detlir Elezi

 

About Advanced Medical Solutions Group plc - see www.admedsol.com
(http://www.admedsol.com)

AMS is an innovative tissue healing medical device company delivering
high-performing solutions that match or surpass market leaders, clinically,
technically, and commercially. From adhesives and sealants, to biosurgical
devices and sutures, AMS's products offer superior usability, quality and
design. AMS's strength lies in combining advanced material science with
applicator device design and development, in collaboration with surgeons and
Key Opinion Leaders, creating differentiated devices that improve patient
outcomes without compromising quality or affordability.

 

AMS's scalable, resilient business model is built on disciplined execution,
portfolio focus, and capital efficiency. Its diversified product and
geographic mix mitigates volatility, ensuring consistent performance even when
individual segments fluctuate. Following its acquisition of Peters Surgical,
AMS is unlocking operational and commercial synergies, accelerating its U.S.
and international expansion, and increasing the percentage of sales made
through its direct sales teams. With surgical products driving the lion's
share of group revenues and a clear top-line trajectory, AMS is positioned for
scalable growth, margin improvement, and long-term value creation.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  TVREAKFEDEFKEFA



            Copyright 2019 Regulatory News Service, all rights reserved